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Abstract
Mycobacterium bovis bacille Calmette-Guérin (BCG) is the most widely used live
attenuated vaccine. However, the correlates of protection and waning of its
immunity against tuberculosis is poorly understood. In this study, we correlated the
longitudinal changes in the magnitude and functional quality of CD4+ and CD8+ T-
cell response over a period of two years after mucosal or parenteral BCG
vaccination with the strength of protection against Mycobacterium tuberculosis in
mice. The BCG vaccination-induced CD4+ and CD8+ T cells exhibited comparable
response kinetics but distinct functional attributes in-terms of IFN-c, IL-2 and TNF-a
co-production and CD62L memory marker expression. Despite a near life-long
BCG persistence and the induction of enduring CD4+ T-cell responses
characterized by IFN-c and/or TNF-a production with comparable protection, the
protective efficacy waned regardless of the route of vaccination. The progressive
decline in the multifactorial functional abilities of CD4+ and CD8+ T cells in-terms of
type-1 cytokine production, proliferation and cytolytic potential corresponded with
the waning of protection against M. tuberculosis infection. In addition, simultaneous
increase in the dysfunctional and terminally-differentiated T cells expressing CTLA-
4, KLRG-1 and IL-10 during the contraction phase of BCG-induced response
coincided with the loss of protection. Our results question the empirical
development of BCG-booster vaccines and emphasize the pursuit of strategies that
maintain superior T-cell functional capacity. Furthermore, our results underscore
the importance of understanding the comprehensive functional dynamics of
OPEN ACCESS
Citation: Nandakumar S, Kannanganat S, Posey
JE, Amara RR, Sable SB (2014) Attrition of T-Cell
Functions and Simultaneous Upregulation of
Inhibitory Markers Correspond with the Waning of
BCG-Induced Protection against Tuberculosis in
Mice. PLoS ONE 9(11): e113951. doi:10.1371/
journal.pone.0113951
Editor: Thomas Jens Scriba, University of Cape
Town, South Africa
Received: July 31, 2014
Accepted: November 1, 2014
Published: November 24, 2014
This is an open-access article, free of all copyright,
and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is
made available under the Creative Commons CC0
public domain dedication.
Data Availability: The authors confirm that all data
underlying the findings are fully available without
restriction. All relevant data are within the paper
and its Supporting Information files.
Funding: The study was supported by Centers for
Disease Control and Prevention (CDC) intramural
funds and the Georgia Research Alliance grant to
SBS, RRA, JEP, and TM Shinnick. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
PLOS ONE | DOI:10.1371/journal.pone.0113951 November 24, 2014 1 / 25
antigen-specific T-cell responses in addition to cytokine polyfunctionality in BCG-
vaccinated hosts while optimizing novel vaccination strategies against tuberculosis.
Introduction
Tuberculosis (TB) is the most devastating bacterial disease of all time and is
responsible for over 1.3 million deaths annually [1]. The only vaccine available
against TB is Mycobacterium bovis Bacille Calmette-Guérin (BCG),6 an attenuated
strain of M. bovis. It is the most widely used vaccine in human history, and is
recommended in .157 countries [2]. BCG efficiently prevents severe forms of
childhood TB [3, 4], but has highly variable efficacy against pulmonary TB in
adolescents and adults [5, 6]. Therefore, extensive research efforts are ongoing to
develop new TB vaccines with superior protective efficacy. Since over 4 billion
individuals have received BCG to date, it is generally accepted that the
development of new vaccination strategies should consider the extensive BCG-
vaccination coverage [7–9]. Accordingly, future vaccination against TB would
involve priming with BCG or an improved live mycobacterial vaccine followed by
a boost with subunit vaccine [9, 10]. A standard approach for screening new
vaccine candidates or strategies to improve BCG-induced immunity starts with
the evaluation of immunogenicity and protective efficacy in animal models of TB,
in particular, the mouse model. However, despite being at the center of new TB
vaccination strategies and its extensive use as a reference standard in many
preclinical and clinical vaccine trials, our knowledge of the protective immune
responses induced by a near century old BCG vaccine is limited in mice and
humans.
Although it is known that BCG induces durable immunity in the mouse model
[11, 12], understanding of the kinetics of immune response in-terms of expansion,
peak and contraction of the T-cell and antibody response is incomplete, and the
optimal time to boost BCG-immunity is uncertain. These gaps have hampered the
development of effective prime-boost vaccination regimens using BCG. As
boosting T-cell responses during the expansion phase may lead to T-cell
exhaustion and activation-induced cell death [13, 14], boosting would be most
desirable after the effector phase of BCG-primed responses and when the memory
T-cell population is established [15]. We reasoned that the evaluation of growth
and persistence of BCG after different routes of administration in mice and the
simultaneous investigation of the kinetics of the magnitude and functional quality
of T-cell responses generated, together with the longitudinal changes in the
protective efficacy against Mycobacterium tuberculosis (Mtb) challenge, may
provide an important insight into the correlates of protection and factors
associated with the waning of BCG-immunity.
The BCG vaccine is most commonly administered to newborns by the
intradermal route. A recent clinical trial in infants has, however, demonstrated
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equivalent protective efficacy using intradermal and percutaneous vaccination
routes [16]. Furthermore, TB is primarily a respiratory disease and it has been
hypothesized that vaccination directed at the respiratory mucosa may provide the
best opportunity for protection against infection with Mtb. The animal
experimental evidence suggests that local immune defense mechanisms might be
crucial for the protective immunity against TB, for example, those stimulated by
mucosal immunization via the lower respiratory tract [17, 18]. Therefore, we
investigated the dynamics of BCG immunity traversing the entire life-span of mice
following intranasal (i.n., mucosal) and subcutaneous (s.c., parenteral) vaccina-
tion.
Our results showed that BCG-induced CD4+ and CD8+ T-cell responses and
protection peak between 12–32 weeks but wanes significantly by 78 weeks
regardless of i.n. or s.c. vaccination. The magnitude of CD4+ and CD8+ T cells
with sound multi-effector capacity in-terms of type-1 cytokine production,
proliferation and cytolytic potential correlated best with protection against Mtb.
Notably, increase in the dysfunctional and terminally-differentiated T cells
coincided with the waning of BCG-induced protection. Our results provide
previously undocumented important insight into how BCG persistence and the
immune senescence affect T-cell functionality in mice and highlight the need to
develop vaccination strategies that prevent T-cell attrition and exhaustion.
Results
BCG persists and induces a durable cell-mediated immune
response in mice
To understand the growth and persistence of BCG after mucosal or parenteral
vaccination, BALB/c mice were vaccinated with 106 BCG Copenhagen colony
forming units (CFU) by i.n. and s.c. route, and BCG titers were determined in the
lung and spleen at 7 different time points. BCG vaccination by the i.n. route
resulted in a high bacillary load in the lung. About 0.2–0.5% of the total BCG
administered following i.n. vaccination was detected in the lung at 48 h, while
BCG could not be detected in the lung at 48 h after s.c. vaccination and only a low
numbers of bacilli (45¡14 CFU) were detected in the lung at week 3 (Fig. 1A). In
the spleen, peak BCG load was found at week 3 after s.c. vaccination while it took
6 weeks for BCG to be detected following i.n. vaccination. The BCG CFUs
declined by week 12 to 32 but persisted at very low or undetectable levels until
week 52. However, by week 78, BCG burden resurged in the two organs of both
vaccinated groups. These results demonstrate the chronic persistence of BCG in
mice.
In parallel, we determined the magnitude and kinetics of BCG-induced cell-
mediated immune response using Mtb whole-cell lysate (WCL) for in vitro
stimulations of lung and spleen cells. The frequencies of WCL-specific IFN-c, IL-
17 and IL-4 spot-forming units (SFU) were measured using a cultured ELISPOT
assay. Although i.n. vaccination-induced total cytokine SFU peaked earlier in the
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lungs (i.e., at week 12) than those produced by s.c. vaccination (which peaked at
week 32), the magnitude of WCL-specific total cytokine response in two organs
was statistically comparable between the routes of vaccination when the total SFU
at 7 different time points were compared (Figure 1B). The total cytokine response
by either route was dominated by higher frequencies and proportions of IFN-c
SFU, although at the peak of response the frequencies of IL-17 SFU were
significantly greater compared to early (6 week) and late (78 week) time points in
the lung. These results suggest that though BCG vaccination induced type-1
immune response declines with age, the nature of response continues to be
predominantly type-1 after i.n. or s.c vaccination
When the antibody response was investigated in the sera of two vaccinated
groups, we observed similar kinetics for WCL-specific IgG-antibody response by
ELISA, but it was significant only in the sera of s.c. BCG-vaccinated mice (Fig.
S1A). The WCL-specific IgG response was characterized by greater proportions of
IgG2a and IgG2b subclass antibodies (Fig. S1B). Overall, these results demonstrate
that i.n. and s.c. BCG vaccination induces a strong cell-mediated response
following early bacillary load and is maintained for more than 8 months. The peak
of immune response in the lung and spleen coincides with decrease in the BCG





T cells exhibit distinct
cytokine profile
To understand the temporal changes in the magnitude and quality of BCG-
induced CD4+ and CD8+ T-cell responses, we evaluated the frequencies of WCL-
and short term culture filtrate (STCF)-specific IFN-c, IL-2 and TNF-a-producing
CD4+ and CD8+ T cells in the lung, spleen, draining and distant lymph nodes
Figure 1. BCG persists and induces a durable cell-mediated immunity in mice. (A–B) BALB/c mice were vaccinated with 16106 CFU of BCG
Copenhagen by intranasal (i.n.) or subcutaneous (s.c.) route. At 7 different time points after vaccination at the same time, mice were euthanized and their
lungs and spleen were isolated. (A) BCG load in the two organs of individual mice was determined. Detection limit of the assay as shown by dotted line was
30 CFU/organ, and data shown are mean CFU ¡ s.e.m. in the lung (left) and spleen (right) from two independent experiments using 5 individually analyzed
mice per group at each time point. The experiment was not performed at the104-week time point. (*P,0.05, ** P,0.01, *** P,0.001, **** P,0.0001 using 1-
way analysis of variance (ANOVA) with Tukey’s post-test). (B) In parallel, pooled cells from the lung (left) or spleen (right) of BCG-vaccinated and naı̈ve mice
(n54/time point/group) were stimulated with WCL in a cultured ELISPOT assay and IFN-c, IL-4 and IL-17A SFU were enumerated. Data are means ¡
s.e.m. of individual cytokine SFU constituting the total cytokine responses of 2 (at week 3, 78 and 104), 3 (at week 32) or 4 (at week 6 and 12) independent
experiments evaluated in triplicate. Responses are significant (P,0.001) in vaccinated compared to naı̈ve mice at 6 time points after week 3 using 1-way
ANOVA with Tukey’s post-test.
doi:10.1371/journal.pone.0113951.g001
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(LNs) by polychromatic flow cytometry. The WCL and STCF represent a
complete repertoire of Mtb antigens as opposed to individual purified antigens or
cocktails of few immunodominant antigens used for in vitro stimulations. We
found comparable magnitudes of WCL-specific cytokine-producing CD4+ T cells
between i.n. and s.c. BCG-vaccinated groups (Fig. 2A), when the frequencies of
IFN-c, IL-2, or TNF-a-expressing CD4+ T cells were analyzed individually in the
lung and spleen. The magnitudes of WCL-specific cytokine-producing CD8+ T
cells were also comparable between the two vaccinated groups. The T-cell
responses peaked at week 32 in the lung and spleen and gradually waned
thereafter, with similar expansion and contraction trend in the two BCG-
vaccinated groups.
When the polyfunctionality of WCL-specific T cells was analyzed in-terms of
co-expression of IFN-c, TNF-a and IL-2 by individual cells [19, 20], we found that
the CD8+ T-cell response in all organs investigated was dominated almost
exclusively by IFN-c single-producers (Fig. 2B and 2C). In contrast, CD4+ T cells
were polyfunctional at the peak, and the response was dominated by higher
magnitudes of IFN-c and TNF-a single- and double-positive cells. These results
demonstrate that BCG vaccination generates CD4+ and CD8+ T-cell responses of
distinct quality. Contrary to the belief that BCG vaccination induces a weak CD8+
T-cell response [21], these data demonstrate the significant presence of IFN-c-
producing CD8+ T cells at peak time points. Although the percentages of WCL-
specific total cytokine-producing cells among CD4+ and CD8+ T cells were
comparable, the frequencies of CD4+ T cells in the T lymphocytes (CD3+) of the
organs investigated were approximately three-fold higher than the frequencies of
CD8+ T cells, thereby confirming the dominance of CD4+ T-cell response after
BCG vaccination during the entire response kinetics in mice.
The BCG-induced early T-cell responses tend to be strongest in the
compartments most proximal to the site of vaccine administration [22], and it is
believed that the distribution of specific T cells may become uniform in the local
and distant compartments as the vaccination-induced immune response matures.
Therefore, we investigated the specific T-cell responses simultaneously in the
draining and distant LNs after i.n. and s.c. BCG vaccination at 5 different time
points. Vaccination by the i.n. route induced higher WCL-specific cytokine-
producing CD4+ and CD8+ T cells in the draining superficial cervical lymph nodes
(CLNs), while s.c. vaccination induced more T-cell responses in the inguinal
lymph nodes (ILNs) which drains the flank (the site of s.c. vaccination) (Fig. 2C).
Responses in the draining CLNs of i.n.-vaccinated and ILNs of s.c.-vaccinated
group also peaked at week 32, but, significantly higher magnitudes (p,0.001) of
WCL-specific T cells were observed only in the corresponding draining LNs as
compared to the distant LNs at all 5 time points investigated (Fig. 2C). These
results demonstrate a near lifelong compartmentalization of T-cell responses in
the draining LNs depending on the route of BCG vaccination.
Furthermore, the mean frequencies of WCL-specific T cells waned after week 32
in the two vaccinated groups with significantly higher polyfunctional CD4+ T cells
at week 32 (p,0.05) compared to week 78 in the three organs investigated,
Dynamics of BCG-Immunity in Mice
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Figure 2. BCG vaccination induces polyfunctional CD4+ but monofunctional CD8+ T-cell response. (A–C) The lung and spleen cells of i.n. and s.c.
BCG-vaccinated mice (n54/time point/group) were stimulated with WCL, and the magnitudes and polyfunctionality of CD3+CD4+ and CD3+CD8+ T cells in-
terms of IFN-c, IL-2 and TNF-a production were determined using polychromatic flow cytometry. (A) The longitudinal changes in the magnitudes of WCL-
specific individual IFN-c, IL-2 or TNF-a-producing cells among CD4+ or CD8+ Tcells in the lung and spleen are plotted. (B) Representative dot plots show the
frequency of WCL-specific IFN-c and IL-2 or IFN-c and TNF-a-producing cells among splenic CD4+ and CD8+ Tcells from one mouse per vaccinated group
at week 32 in comparison with age-matched naı̈ve control, and the distributions of single, double and triple-cytokine-producers are illustrated. (C) The
magnitudes of 7 possible combinations of WCL-specific cytokine-producing subsets constituting total cytokine+ CD4+ or CD8+ T cells in the lung, spleen,
cervical lymph node (CLN) and inguinal lymph node (ILN) are depicted. The data (A, C) are mean ¡ s.e.m. responses of 2 (at week 3, 78 and 104), 3 (at
week 32) or 4 (at week 6 and 12) independent experiments.
doi:10.1371/journal.pone.0113951.g002
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demonstrating decline in the magnitude and quality of BCG vaccination-induced
T-cell response. By week 104, the magnitude of WCL-specific cytokine-expressing
CD4+ and CD8+ T cells had waned to levels similar to those observed at week 3
(Fig. 2C), and we observed similar T-cell cytokine response dynamics using Mtb
STCF (Fig. S2A and S2B). However, in contrast, we did not find any significant
difference in the magnitude of WCL-specific cytokine-expressing T cells in young
(8-week-old) and old (104-week-old) mice, 6 weeks after BCG vaccination (Fig.
S2C), indicating that the decline in the immune response with time after BCG
vaccination was not merely due to age-related senescence. Together, these data
demonstrate the gradual waning of BCG-induced CD4+ and CD8+ T-cell





T cells express cytolytic potential
that wanes with time
To further characterize the temporal changes in the quality of BCG-induced T
cells, we assessed the degranulation potential of CD4+ and CD8+ T cells, measured
as the surface mobilization of CD107a and CD107b [19, 23, 24]. The WCL-specific
CD4+ and CD8+ T cells in the lung and spleen of BCG-vaccinated mice expressed
CD107 (Fig. 3A), and the route of administration did not affect their
degranulation potential. Furthermore, both CD4+ and CD8+ T cells purified from
the two organs of vaccinated groups induced cytolysis in target cells based on the
up-regulation of apoptosis marker annexin-V on the surface of WCL-pulsed
bone-marrow-derived dendritic cells (Fig. 3B), lung macrophages (Fig. S3A), or
peritoneal macrophages (Fig. S3B) upon co-culture. The degranulation potential
of both T-cell subsets peaked at week 32, and the percentages of WCL-specific
CD107-expressing T cells declined significantly by week 78 (p,0.05 for CD4+ and





T cells exhibit distinct memory
phenotype in-terms of CD62L expression and their proliferative
potential decreases during waning
Next, we assessed the association between contracting T-cell responses and other
functional abilities such as proliferative potential and up-regulation of memory
markers by T cells. Using CFSE-dilution assay, we found the highest WCL-specific
proliferative ability of CD4+ and CD8+ T cells in vitro at the expansion phase
(week 12) after i.n. or s.c. vaccination (Fig. 4A and 4B). Thereafter, the
proliferation decreased at week 32 and further waned significantly by week 52.
Simultaneously, we investigated the memory phenotype by assessing the
expression of CD44 and CD62L or CCR7 [25], and found that .90% of lung and
spleen WCL-specific IFN-c+CD4+ T cells expressed CD44+CD62L2 activated
effector or effector memory (TEM) phenotype at week 12 and 52 (Fig. 4C and 4D).
Higher percentages (22.45–41.60%) of WCL-specific IFN-c+CD8+ T cells
expressed CD44+CD62+ central memory (TCM) phenotype (Fig. 4D), but, both
Dynamics of BCG-Immunity in Mice
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CD4+ and CD8+ T cells did not produce significant IL-2 or express another
classical TCM marker, CCR-7, during the contraction phase (Fig. S4A–C). These
results suggest generation of predominantly effector/TEM responses but weak TCM
responses following BCG vaccination.
T-cell dysfunction markers are up-regulated during waning of
BCG responses
Chronic infections often lead to impaired T-cell responses characterized by a
progressive loss of T-cell functions, terminal differentiation and eventual T-cell
exhaustion [26–29]. Since BCG chronically persists in mice, we sought to
determine whether up-regulation of T-cell inhibitory receptors and markers of T-
cell dysfunction corresponded with the contraction of BCG-induced T-cell
response and simultaneous decrease in T-cell functionality. We investigated the
surface expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed
cell death protein 1 (PD-1), and killer cell lectin-like receptor subfamily G
member 1 (KLRG-1), and the intracellular production of IL-10 by T cells. The
KLRG-1 and CTLA-4 expression on CD4+ and CD8+ T cells of vaccinated mice
increased significantly by week 78 compared to week 12, and compared to age-
matched naı̈ve mice (p,0.05) (Fig. 5A–5D), suggesting that these changes are not
simply age related [30]. Following WCL stimulation, .97% of CTLA-4+ or
KLRG-1+ T-cell subsets did not produce IFN-c, IL-2 or TNF-a (data not shown).
Figure 3. BCG vaccination-induced CD4+ and CD8+ T cells express cytolytic potentials. (A–B) The lung and spleen cells from i.n. or s.c. BCG-
vaccinated mice were stimulated with WCL after staining with CD107a and CD107b and the CD107 a/b expression was evaluated on Tcells (gated on CD3+
cells). (A) The CD107a/b expression on CD4+ Tcells of lung and spleen of one representative mouse from the control and vaccinated groups at week 32 is
shown. The green dots represent the WCL-specific IFN-c, IL-2 and/or TNF-a-producing cells. (B) Representative histograms show the annexin-V expression
on the cell surface of WCL-pulsed target cells (i.e., BMDCs gated on CD32CD11c+ cells) after co-culture with the purified CD4+ (left) or CD8+ (right) T cells
(at 1:20 ratio) from the pooled lungs (upper panel) or spleens (lower panel) of BCG-vaccinated or age-matched naı̈ve mice (n53/group). (*P,0.05, **
P,0.01, using 1-way ANOVA with Tukey’s post-test and by comparing frequencies of annexin-V+ BMDCs (CD32CD11c+ cells) of vaccinated mice and naive
controls). (C) The summary of temporal changes in the magnitudes (%) of CD107 a/b upregulation on CD4+ (left) or CD8+ (right) Tcells expressing IFN-c, IL-
2 and/or TNF-a after WCL-stimulation. The data are mean ¡ s.e.m. responses of 2 (at week 3, 6, 78 and 104) or 3 (at week 32 and 12) independent
experiments (n54/time point/group). (*P,0.05, ** P,0.01, using 1-way ANOVA with Tukey’s post-test, depicting significantly less responses compared to
corresponding 32-week time points).
doi:10.1371/journal.pone.0113951.g003
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However, we did not observe any significant increase in the percentages of PD-1-
expressing CD4+ or CD8+ T cells during the contraction phase in BCG-vaccinated
mice (Fig. 5C). Apart from the inhibitory-receptor signaling, cytokines like IL-10
also exert suppressive effect and mycobacterial reactivation [31, 32], and we found
increased WCL-specific IL-10-producing CD4+ and CD8+ T cells at week 52 as
compared to week 12 in BCG-vaccinated mice (Fig. 5E and 5F). Collectively, these
results suggest that the waning of BCG-induced T-cell responses corresponds with
the increased frequency of inhibitory markers-expressing CD4+ and CD8+ T cells.
Of importance, in vitro rIL-2 treatment of the lung and spleen cells significantly
increased WCL-specific IFN-c and IL-17 SFU and the total cytokine (IFN-c, IL-2
Figure 4. BCG-induced T cells predominantly exhibit effector or effector memory phenotype and their proliferative potential wanes with time. (A–
B) The proliferation of CD4+ and CD8+ T cells from the lung and spleen of the BCG-vaccinated mice was investigated based on CFSE-dilution at 72 h
following WCL or no antigen stimulation. (A) Representative plots illustrate the proliferation of pooled lung CD4+ and CD8+ Tcells of vaccinated mice (n54)
from one experiment at the expansion and contraction phase. (B) The longitudinal changes in the proliferative potential of the lung and spleen CD4+ or CD8+
T cells from the two vaccinated groups at 4 different time points were summarized and are presented as the fold increase in proliferation compared to
unstimulated controls (*P,0.05, **P,0.01 using 1-way ANOVA with Tukey’s post-test compared to corresponding week 12). (C) The CD44 and CD62L
expression on the pooled splenic CD4+ and CD8+ T cells of vaccinated mice (n54) from one representative experiment at the expansion and contraction
phase are shown. The green dots represent WCL-specific IFN-c-producing Tcells. (D) The magnitudes of WCL-specific IFN-c-producing CD44+CD62L+ and
CD44+CD62L2 CD4+ and CD8+ Tcells from the lung and spleen of two groups at week 12 and 52. The data in (B) and (D) are mean ¡ s.e.m. responses of 2
independent experiments using pooled organ cells (n54 mice/time point/group).
doi:10.1371/journal.pone.0113951.g004
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or TNF-a) response at week 78 (Fig. 5G and 5H), indicating that the
dysfunctional T-cell responses could be partly rescued by IL-2 therapy.
Waning of BCG-induced protection against Mtb coincides with
decreased T-cell functionality
To understand the kinetics and durability of BCG-induced protection, we
challenged i.n. and s.c. BCG-vaccinated mice with Mtb Erdman at different time
points after vaccination, and Mtb load was determined in the lung and spleen 6
weeks later. Our data demonstrate that the route of vaccination did not
Figure 5. T-cell dysfunction markers are up-regulated during waning of BCG responses. (A) The expression of KLRG-1 on the pooled spleen Tcells of
age-matched naı̈ve, i.n. or s.c. BCG-vaccinated mice (n54) at week 78. (B) Longitudinal changes in the magnitude of KLRG-1+ CD4+ and CD8+ Tcells from
the lung and spleen. (C) CTLA-4 and PD-1 expression on the pooled splenic CD4+ T cells of vaccinated or age-matched naive mice (n54) at week 78. (D)
Summary of magnitude of CTLA-4+ CD4+ and CD8+ Tcells in the lung and spleen. (E) The WCL-specific IL-10 production by the pooled splenic CD4+ Tcells
of vaccinated or age-matched naı̈ve mice. (F) Summary of magnitude of WCL-specific IL-10+ CD4+ and CD8+ T cells in the lung and spleen. (G–H) The
spleen and lung cells isolated from i.n. BCG-vaccinated mice at week 78 were treated with rIL-2 to evaluate potential to reinvigorate WCL-specific CD4+ and
CD8+ T-cell responses. (G) The WCL-specific IFN-c, IL-4 and IL-17 SFU after treatment with or without rIL-2. (H) The magnitude of WCL-specific cytokine-
producing 7 subsets of CD4+ and CD8+ T cells by flow cytometry. The data in figure B, D, F are mean ¡ s.e.m. responses of 2 independent experiments
using pooled organ cells (n54 mice/time point/group). * P,0.05, ** P,0.01 compared to the corresponding 12-week time point by 1-way ANOVA with
Tukey’s post-test. 5G, H are mean ¡ s.e.m responses of pooled cells evaluated in triplicates. *Significant using 1-way ANOVA with Tukey’s post-test.
doi:10.1371/journal.pone.0113951.g005
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significantly alter the protective efficacy against Mtb at all eight infection time
points investigated compared to age-matched naı̈ve controls (Fig. 6A). The
protection was found between 6–52 weeks with maximum efficacy at week 32
(log10 CFU reduction 1.77–2.1 in lung and 2.34–2.56 in spleen), but eventually
waned by week 78. Previously elderly (2-year-old) mice have been shown to
effectively control early Mtb infection [33], and in our model, we consistently
found low CFU burden in the lung or spleen of 104-week-old elderly naı̈ve mice
compared to simultaneously infected 12-week-old young control mice 6 weeks
Figure 6. Waning of BCG-induced protection against Mtb coincides with decreased T-cell functional capacity. (A–C) BCG-vaccinated or age-
matched naı̈ve mice were infected with Mtb Erdman, and 6 weeks later the spleen and lungs were isolated. (A) Differences in Mtb load between vaccinated
and control mice are shown. The data are mean ¡ s.e.m.Mtb CFU in each organ at eight different time points involving two to four independent experiments
each using five individually analyzed mice per time point. (*P,0.05, ** P,0.01, *** P,0.001, compared to the corresponding age-matched naı̈ve control by
Kruskal-Wallis test followed by Dunn’s post-test). (B) The longitudinal changes in the frequency of rESAT-6+rCFP-10-specific total CD4+ cytokine+ (of IFN-c,
IL-2 and TNF-a) T cells from the lung (upper panel) and spleen (lower panel) of vaccinated and naı̈ve mice 6 weeks after challenge (*P,0.05, ** P,0.01
compared to the corresponding week 32 BCG-vaccinated mice by 1-way ANOVA and Tukey’s post-test). At the 32-week time point, rESAT-6+rCFP-10-
specific responses in naı̈ve mice are statistically higher compared to the corresponding vaccinated groups (P,0.05). (C) The magnitudes of WCL-specific
total CD4+ cytokine+ T cells before and 6 weeks after Mtb challenge. The data are mean ¡ s.e.m. responses measured by intracellular cytokine staining
(ICS) of four mice per time point. (*P,0.05 comparing pre- and post-challenge WCL-specific responses using 1-way ANOVA and Tukey’s post-test) (D) The
schematic summary of longitudinal changes in BCG load in the lung and spleen of i.n. and s.c. BCG-vaccinated mice over a period of 2 years and its
correlation with the magnitude and functional capacity of T cells and levels of protection against Mtb infection.
doi:10.1371/journal.pone.0113951.g006
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after challenge (data not shown), confirming that the low CFU levels in week-104
groups (Fig. 6A) were not due to failed infections. The frequency of ESAT-
6+CFP-10-specific cytokine-producing T cells in the lung and spleen evaluated as
a surrogate of Mtb load after challenge [34] correlated inversely with the degree of
protection (Fig. 6B and S5A), with significantly more ESAT-6+CFP-10-specific
CD4+ T cells in week-3 and -78 as compared to week-32 groups, 6 weeks post-
challenge. Furthermore, Mtb challenge during the expansion phase of BCG-
induced response resulted in a better recall of WCL-specific T-cell responses in the
two organs (Fig. 6C and S5B). Conversely, challenge during the contraction phase
demonstrated decreased frequency of WCL-specific cytokine-producing CD4+
and CD8+ T cells compared to the levels observed pre-challenge. Together, these
results suggest that the degree of BCG-induced protection correlates with the
magnitude and intact functional capability of specific CD4+ and CD8+ T cells
(Fig. 6D).
Discussion
We found increased BCG load in the lung as compared to spleen following i.n.
vaccination while s.c. vaccination resulted in relatively higher levels in the spleen
as compared to lung by 3 weeks. Similar results have been reported earlier after
i.n. vaccination [35], and it is known that following s.c. vaccination initial BCG
multiplication occurs in the draining ILN and results in higher bacterial
dissemination to the spleen than the lung by week 4 [36]. It has been suggested
that BCG chronically persists in the draining lymph nodes of mice after s.c.
vaccination [12], and may serve as a reservoir for dissemination to the lung and
spleen. In our study BCG sporadically disseminated to the lung in low numbers
during early and late time points after s.c. vaccination. Previous studies of the
shorter duration have suggested that BCG never or only rarely disseminates to the
lung after s.c. vaccination [37], while others have reported that BCG disseminates
to the lung in low numbers during a 20-week study [36]. In view of the recent
report of bone marrow stem cells as a niche for dormant Mtb, further studies are
required to characterize reservoirs of persistent BCG in mice [38]. Despite a
significant decline in the BCG-burden by week 12 and the persistence of bacteria
in low numbers thereafter at week 32–52, BCG-induced Mtb-specific T-cell
responses and the degree of protection against subsequent Mtb challenge peaked
at week 12–32 in the lung and spleen in our study. This occurred regardless of the
early differences in the tissue localization of BCG-burden and the pronounced
differences in the location of specific T cells in the draining LNs depending on the
route of vaccination. We did not find any significant difference in the strength of
protection against Mtb challenge between i.n. and s.c. BCG vaccination at all-time
points investigated using a moderate vaccine dose. The dose and route of BCG
administration and consequently the tissue localization have been previously
suggested to have a minor impact on the protective immunity against TB [39, 40].
Likewise, in our model, no direct correlation was found between the extents of
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BCG antigenic load and the magnitudes of BCG-induced T-cell responses or the
levels of protection against Mtb. In fact, the peak of T-cell responses succeeded
early BCG load and waned despite relatively higher BCG titers at week 78.
The BCG-induced T-cell responses in our study were characterized predomi-
nantly by IFN-c and/or TNF-a-producing CD4+ T cells and single IFN-c-positive
CD8+ T cells. Although the importance of CD4+ T cells in protection against Mtb
has been widely accepted, the role of subunit vaccine-induced CD8+ T-cell
response has been recently debated [41, 42]. Nonetheless, BCG vaccination-
induced CD8+ T-cell response has been previously shown to play an important
part in the protection against Mtb [21, 43, 44]. Multiple studies have shown that
IFN-c and TNF-a cytokines are required for immunity against Mtb infection
[45, 46]. In contrast, several other studies have shown that the magnitudes of IFN-
c-producing T cells or in vitro cytokine levels do not correlate with the degree of
protection against TB [34, 40]. Recently, IFN-c, TNF-a, and IL-2 co-expression by
individual polyfunctional CD4+ T cells has been proposed as a marker of BCG-
induced protective immunity [20]. In our study, the frequency of Mtb-specific
total or polyfunctional Th1 cytokine-producing CD4+ T cells was about two-fold
more at the peak (week 32) compared to the expansion phase (week 12), but the
levels of protection after Mtb challenge was not significantly different.
Furthermore, the protection was higher at week 12 compared to week 78, despite
comparable magnitudes of BCG-induced T-cell responses. Hence, the correlation
between the magnitude of total cytokine-producing T cells or polyfunctional
CD4+ T cells and the degree of protection against Mtb challenge, although
positive, appears to be rather weak. Previously, it has been reported that the
frequency of BCG-specific CD4+, CD8+, and cd T cells and polyfunctional Th1
cytokine-producing CD4+ T cells in the blood does not correlate with the
protection against TB in BCG-vaccinated children [47]. The increased BCG-
burden during the contraction phase and the concurrent decrease in the
magnitude and functionality of type-1 cytokine-producing specific T cells is in
agreement with previously described negative association between the functional
capacity of Mtb-specific T cells and Mtb load in the sputum of TB patients
[48, 49].
It is known that persistent, low-dose antigenic stimulation throughout life may
compromise antigen-specific T cells in two ways. First, they may become
functionally exhausted and lose essential functional activity that is necessary for
immune protection. Second, repeated T-cell stimulation can lead to a loss of the
replicative capacity of some antigen-specific T cell populations, as a result of
telomere erosion and/or unrepaired DNA damage, a process known as replicative
senescence (reviewed in [30]). The induction of senescence in T cells is also
known to limit the long-term persistence of immune responses during aging [50].
Therefore, the attrition of specific T-cell responses discerned in our study can be
attributed in part to the onset of immune senescence associated with the
advancing age in BCG-vaccinated mice. The terminally-differentiated and
senescent T cells are characterized by the up-regulation of KLRG-1 expression
[51], while functionally exhausted T cells are defined by the early loss of IL-2
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production, decreased proliferation, and the increased expression of inhibitory
markers like CTLA-4 and PD-1 with low levels of TCM markers CD62L and CCR-7
[27, 52, 53]. Although the terms senescence and exhaustion are often used
interchangeably when referring to highly differentiated T cells, available data
suggest that both processes are regulated independently of each other [30]. It
should be noted that the onset of the contraction of specific T-cell responses in
our study was chronicled at the week 52 in BCG-vaccinated mice i.e., at the adult
mid-life, and significantly increased expression of KLRG-1 and CTLA-4 was found
during the contraction phase on the T cells of BCG-vaccinated mice compared to
those of age-matched naı̈ve mice. In addition, we found comparable magnitudes
of specific T-cell cytokine responses in elderly (104-week-old) and younger (8-
week-old) mice, 6 weeks post BCG vaccination. Old mice (24-month-old) have
been previously shown to effectively control early Mtb infection [33, 54], and the
BCG vaccination has been found to be equally protective in young, adult and old
guinea pigs against TB [55]. Therefore, decreased functional abilities of T cells
during the contraction phase of BCG-response observed in our study may not be
only due to the advanced-age-related senescence in mice, and it is probable that
the chronic persistence of BCG with low grade continuous antigen stimulation
throughout life contributes to the attrition of T-cell functions and precipitates
immune senescence.
Like Mtb infection [25], BCG-induced responses in our study were dominated
by CD4+ effector/TEM subset secreting IFN-c and/or TNF-a [56], and the
frequency of IL-2+ T cells was much lower compared to that reported previously
after protective subunit vaccination of mice [57]. Even though CD44+CD62L+
expression on CD8+ T cells in our study suggested an acquisition of the TCM
phenotype [58], these cells did not produce IL-2 during the contraction phase and
showed concurrent impaired proliferative capacity contrary to the earlier reported
characteristics of classical TCM cells [59, 60]. Multiple human and mouse studies
have also shown that BCG primarily promotes effector/TEM cells [12, 61]. Many
factors may influence development of a long-lived and high-quality memory T
cells and of these, antigen load and persistence may be the most important ones
[62]. Our study provides a direct evidence for the chronic persistence of BCG load
and its correlation with the poor central memory T-cell responses in mice.
Previous observations of improved TCM responses after clearance of Mtb or BCG
in mice and their association with protection provide additional evidence for the
correlation between chronic persistence of BCG and poor TCM responses [63–65].
Paradoxically, the protective efficacy of BCG in mice also appears to be dependent
on the presence of viable bacilli [36] and consequently on the TEM responses.
Recently, greater CD4+ TCM responses induced by recombinant BCG DureC::hly
vaccine (rBCG) have been shown to be responsible for superior protection
compared to canonical BCG against Mtb and the TCM responses are shown to
coincide with the faster clearance of rBCG in mice [66]. It has been suggested that
the canonical BCG is cleared more rapidly in humans than mice and influence the
memory phenotype (especially TCM phenotype) of BCG-specific CD4
+ T cells
[15]. However, in this study [15], specific CD4+ T cells expressed characteristics of
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both central memory (CCR7+ expression) and effector memory (predominant
cytokine IFN-c and cytotoxic marker expression) following contraction and
exhibited a more complex and different phenotype than the classical IL-2+TCM
cells. The growth and persistence of BCG in humans is not known with certainty,
and reports of BCG-lymphadenitis or dissemination years after BCG vaccination
are used to support a relatively long life-span of this vaccine in humans [67–69].
On the other hand, one would argue that disseminated BCG infections in HIV
infected patients and children are not frequent complications or common findings
[70]; supporting the viewpoint that viable BCG probably does not persist in
children for a long period of time after vaccination. We agree that some aspects of
the BCG growth observed in mice such as the resurgence of BCG-burden during
the contraction phase of immune response may not necessarily occur in
immunocompetent humans and rather this may be a phenomenon seen only in
susceptible animal models and children with immune gene deficiency [71]. Like
reported observations in mice [7], BCG-induced immunity is thought to wane
with time after vaccination at birth in humans and is generally considered to last
no more than 10–15 year [72]. However, the time frame for the waning of BCG in
humans is still a subject of debate, and a long-term protective efficacy of BCG in
some populations has been reported [73]. It is generally agreed, nevertheless, that
the waning of BCG-induced protection through childhood and young adult life
coincides with the gradual increase in TB incidence in highly TB-endemic regions,
which reaches peak in the 25–35-year-old age group [8]. Overall, caution is
merited while comparing longitudinal changes in BCG-induced immune
responses in mice with those observed in humans.
The persistent antigen load in chronic viral infections and active TB in humans
is known to be associated with a progressive impairment of T-cell responses
[26, 53, 74], and up-regulation of markers of T-cell dysfunction, terminal
differentiation and exhaustion [52, 75, 76]. In our study, BCG-induced response
during the contraction phase was characterized by an increased expression of
KLRG-1, CTLA-4 and IL-10 production, reduced ability to recall T-cell responses
following Mtb challenge and loss of protection against Mtb. However, we did not
observe significant changes in the PD-1 expression on CD4+ or CD8+ T cells
during the three phases of BCG-induced response and our results are at odds with
the previous study [77], which documented PD-1 expression on T cells after a
high-dose intravenous BCG infection of mice. It has been previously shown that
the BCG-vaccinated adults harbor early-stage-differentiated, low PD-1-expressing
antigen-specific effector memory CD4+ T cells while BCG-vaccinated, latent TB
infected (LTBI) adults had late-stage-differentiated PD-1+ T cells [78], and the
advanced TB patients harbor PD-1+ severely exhausted T cells with compromised
IFN-c production [74, 79]. It is tempting to speculate that the resurgence of BCG
growth at the late time point (78 weeks) in our study could be due to the lack of
immune control and attrition of T-cell functions. However, since BCG CFUs were
not enumerated at 104-week time point, this needs further investigation. Overall,
our results suggest that the multifactorial functional ability of BCG-induced T
cells in-terms of type-1 cytokine production, proliferative and cytotoxic potential
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and ability to recall immune-mediators post Mtb challenge likely correlate with
the superior protection against TB. These results also suggest a need to look
beyond the quantitative measures of few cytokine markers of vaccine-induced Th1
cells, with improved focus on the combined functional abilities of different
immune subsets.
Our results have several implications for the development of effective
vaccination strategies using BCG or other live TB vaccines. Although parenteral
BCG vaccination via skin was sufficient to induce a durable protective immunity
in the lung, our observation of the life-long route-specific compartmentalization
of T-cell responses in the draining LNs has important ramifications for the
development of effective prime-boost vaccination strategies. The administration
of a booster vaccine by a homologous route, involving the same draining LNs as
the primer vaccine, may be an effective strategy to induce a superior booster effect
in prime-boost scenarios. The ideal time to boost BCG-primed T-cell responses in
the mouse model might be after the expansion and peak phase i.e. at week 52 or
thereafter. This viewpoint is further supported by a recent data from our
laboratory, where boosting with Apa (Rv1860)-based subunit vaccine during the
contraction phase offered a stronger boost and imparted significant protection
[80]. The data also reinforces the fact that in most published vaccine studies, mice
are challenged far too quickly [9] and the longer vaccination-to-challenge
intervals, such as 6–8 months after BCG vaccination, will provide better
information about the protective efficacy of preclinical vaccines against Mtb
infection in the mouse model. Further, the loss of protection during the chronic
phase of BCG growth and the corresponding increase in KLRG-1+ and CTLA-4+ T
cells highlight the need to develop strategies which can overcome these inhibitory
signals and promote a highly distinct or superior quality T-cell responses. One
such approach based on our observations could be a rIL-2 therapy to rescue
dysfunctional T cells [81]. Recently, it was demonstrated that BCG-mediated
protection is lost as Mtb infection enters the chronic phase in C57BL/6 mice, but a
single boost with H1-subunit vaccine could selectively promote CD4+KLRG-
12IL-2+ TCM cells and impart long-term protection [82], which suggests that
strategies to prolong BCG-efficacy without T-cell exhaustion could be pursued.
Overall, our study provided a comprehensive portrait of longitudinal changes
in the specific T-cell responses following BCG vaccination in the mouse model.
The data suggest an association between the functional capacities of BCG-induced
T cells and levels of protection against Mtb and provide a rationale for future
longitudinal studies optimizing novel prime-boost vaccination strategies and
understanding the mechanisms of loss of BCG-induced protection in young
adults from the regions of high prevalence of Mtb infections. It is a well-
established fact that BCG provides the lowest level of protection against TB in the
regions with the highest prevalence of latent infection [5], and the caveat is that
the certain aspects of the dynamics of BCG-immunity in mice may not inevitably
embody human responses. In the light of results presented here, however, it is
reasonable to envisage that repeated Mtb and environmental mycobacteria
exposure and prevalent latent infections in these human populations may further
Dynamics of BCG-Immunity in Mice
PLOS ONE | DOI:10.1371/journal.pone.0113951 November 24, 2014 16 / 25
exacerbate T-cell attrition and exhaustion leading to breakdown in BCG-induced
anti-TB immunity. Since BCG vaccination-induced T-cell responses mirror those
reported by an actual Mtb infection in mice and humans, our results indicate that
a successful novel TB vaccine should re-educate the immune system rather than
reproducing the natural immune responses generated by Mtb infection.
Materials and Methods
Ethics Statement
All animal experiments performed were in strict accordance with the guidelines of
the U.S. Public Health Service Policy on the Humane Care and Use of Animals
and the Guide for the Humane Care and Use of Laboratory Animals. All
procedures including euthanasia by exsanguination under isoflurane inhalation
anesthesia were approved and supervised by the Institutional Animal Care and
Use Committee of CDC (Approval numbers SABMOUC1664, 1847, 1490 and
SHIMOUC 1422). We obtained 6–8-week-old female BALB/c mice from the
Charles River Laboratories. Experimental mice were housed under specific-
pathogen-free conditions in the animal biosafety laboratory (ABSL)-II and ABSL-
III facilities of the Centers for Disease Control and Prevention (CDC) along with
sentinel mice.
BCG Vaccination and Mtb Infection
M. bovis BCG Copenhagen vaccine (Danish 1331 strain, Staten Serum Institute,
Copenhagen, Denmark) and Mtb Erdman challenge strain were provided by the
Center for Biologics Evaluation and Research, Food and Drug Administration,
Bethesda, MD. For vaccinations of mice, lyophilized BCG was suspended in
vaccine diluent (diluted Sauton medium) provided by the supplier. I.n.
vaccination was carried out by applying a total of 30 ml of BCG vaccine
suspension containing 16106 CFU drop-wise to the external nares (15 ml per
nostril) using a fine tip micropipette and allowing the mouse to inhale the
suspension into the lungs naturally [22]. For s.c. vaccination, 50 ml of a BCG
suspension was injected above the gluteus superficialis and biceps femoralis
muscles of both hind legs using a 26-gauge needle to deliver a total of
16106 CFU. The vaccine diluent-administered or naı̈ve mice served as controls.
BCG-vaccinated and control mice were challenged by the airway i.n. route to
deliver 56104 CFU of Mtb Erdman [22, 80]. At 48 h following challenge,
approximately 0.5% (mean 250 CFU) of the total CFU delivered could be
cultured from the lungs. In BCG-vaccinated mice bacillary titers were determined
by plating serial dilutions of organ homogenates onto Middlebrook 7H10 agar
(BD-Biosciences) supplemented with 0?2% (v/v) glycerol and 10% (v/v) Oleic
Albumin Dextrose Catalase (OADC) growth supplement. The BCG growth on
plates was confirmed by spoligotyping to rule out atypical mycobacterial co-
infection in mice. In Mtb-challenged mice, organ CFU were determined on
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Middlebrook 7H10 agar supplemented with OADC, 10 mg ml21 ampicillin and
50 mg ml21 cycloheximide with or without 2 mg ml21 thiophene 2 carboxylic acid
hydrazide (TCH). Mycobacterial colonies were enumerated after 4 weeks of
incubation at 37 C̊.
ELISPOT assay
Commercially available ELISPOT kits (BD-Biosciences and eBioscience) were
used to investigate IFN-c, IL-2, IL-4 or IL-17A secretion by mouse organ cells
according to the manufacturer’s protocol as described before [22, 80]. See Text S1
for details.
Flow cytometry
Mouse organ cells were stained with specific fluorochrome-labeled antibodies to
assess the expression of cell surface markers and intracellular cytokines using
polychromatic flow cytometry as described earlier [19, 80]. See Text S1 for details.
ELISA
Serum antibody ELISA was carried out as described previously [83], using
5 mg ml21 of Mtb antigen for coating and HRP-conjugated anti-mouse IgG
(Sigma-Aldrich), IgG1, IgG2a (BD-Pharmingen) and IgG2b (Santa Cruz Biotech)
antibodies for detection.
CFSE dilution assay
Cells were stained with 5 mM CFSE (Invitrogen) in a total volume of 1 ml for
5 min in the dark [84]. The reaction was stopped using cold PBS containing 5%
FBS. The cells were stimulated with or without Mtb antigens (1 mg ml21) for 72 h
in the presence of 5% CO2 at 37 C̊. The cells were washed, stained with desired
anti-mouse fluorochrome-labeled antibodies and acquired using FACS Caliber
flow cytometer and analyzed using FlowJo software.
Cytotoxicity assay
Syngeneic BMDCs were generated using femur bone-marrow cells as described
previously [85]. The lung and peritoneal macrophages were obtained after
overnight adherence of lung cells or peritoneal lavage of naı̈ve mice. These antigen
presenting cells were pulsed with WCL (10 mg ml21) for 4 h at 37 C̊ in RPMI-
1640. Cells were washed (64) and co-cultured with CD4+ or CD8+ T cells
purified using Dynabeads-untouched-T-cell purification kits (Life Technologies)
from the lung or spleen cells of BCG or naı̈ve mice for 12 h at 37 C̊. The target
and effector cell ratios of 1:0, 1:1, 1:10 and 1:20 were used. The apoptosis of the
target cells after co-culture was assessed using mouse annexin-V staining kit (BD-
Biosciences) and polychromatic flow cytometry according to the manufacturer’s
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instructions. In addition to the annexin-V (FITC) and propidium iodide (PI), the
cells were stained with antibodies against CD11c (Alexa Fluor-700-clone HL3),
CD11b (PE-Cy7-clone M1/70), F4/80 (APC-clone BM8) and CD4 (PerCP-clone
RM4-5) or CD8 (PE–clone 53-6.7). The cells were acquired using LSR II flow
cytometer and the data was analyzed by Flowjo software.
In vitro inhibitory receptor blockade and IL-2 treatment
We investigated the potential of rIL-2, anti-KLRG-1 and anti-CTLA-4 antibody
treatment to reinvigorate T-cell response in in vitro cultures at the 78 week time
point after BCG vaccination of mice. We incubated lung or spleen cells with
10 ng mL21 of rIL-2, with or without WCL stimulation, in ELISPOT and ICS
assays. In vitro KLRG-1 or CTLA-4 blockade using corresponding antibodies was
also attempted [86, 87]. Different concentrations of KLRG-1 antibody (2F1;
eBiosceinces) up to 20 mg mL21 had no detectable effect on the cytokine response
in these assays; however, 4F10 CTLA-4 antibody (BD-Biosciences) or purified Fab
(20 mg mL21, using Pierce Fab Micro Preparation kit, Thermo Fisher) completely
inhibited WCL-specific T-cell cytokine response suggesting inhibitory rather than
blocking effect of this antibody [88].
Statistical analyses
Differences in immune response between groups or time points were assessed by
1-way ANOVA followed by Tukey’s post-test and the protective efficacies between
vaccinated and control groups were compared by the nonparametric Kruskal-
Wallis test followed by the Dunn’s post-test (GraphPad Prism program). Unless
indicated, all immune response data are presented after subtracting no antigen
control values. The P value ,0.05 was considered significant.
Supporting Information
Figure S1. Longitudinal changes in the serum antibody response following
BCG vaccination. BALB/c mice vaccinated with 16106 CFU BCG by i.n. or s.c.
route were euthanized at seven different time points by exsanguination and the
serum was isolated from the cardiac blood and evaluated for the antibody
response by ELISA. The WCL-specific total IgG (A) or three different IgG subclass
(B) levels in the serum of vaccinated or naı̈ve mice are plotted as an absorbance at
492 nm. The data are mean ¡ SEM responses of 5–32 individually analyzed mice
per time point per group.
doi:10.1371/journal.pone.0113951.s001 (TIF)
Figure S2. Longitudinal changes in the T-cell responses following BCG
vaccination. (A–B) The lung and spleen cells of i.n. and s.c. BCG-vaccinated mice
(n54/time point/group) were stimulated with Mtb STCF, and the magnitudes and
polyfunctionality of CD3+CD4+ and CD3+CD8+ T cells in-terms of IFN-c, IL-2
and TNF-a production were determined using polychromatic flow cytometry.
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The longitudinal changes in the magnitudes of STCF-specific total cytokine
producing CD4+ (A) or CD8+ (B) T cells in the lung (top) and spleen (bottom)
are plotted as bar graph while changes in the magnitude of STCF-specific single-,
double-, triple-cytokine-producers are plotted as an overlay line graph. The data
(A, B) are mean ¡ s.e.m. responses of 2 (at week 3, 6, 12, 78 and 104) or 3 (at
week 32 and 52) independent experiments. *Significantly less total cytokine
response was found compared to week 32 using 1-way ANOVA with Tukey’s
post-test; * P,0.05 and ** P,0.01. (C) The effect of age and time on the BCG
vaccination-induced T-cell response. The magnitudes of total cytokine-producing
CD4+ T cells in the lungs and spleen after WCL stimulation were investigated at
the age and time indicated in three BCG-vaccinated groups (n54 mice/time
point/group). These groups include i) 8-week-old mice vaccinated with BCG and
sacrificed 6 weeks later, ii) 8-week-old mice vaccinated with BCG and sacrificed
104 weeks later, and iii) 104-week-old mice vaccinated with BCG and sacrificed 6
weeks later to investigate T-cell response. *Significance in comparison with the
group of mice vaccinated at 104 weeks of age and sacrificed 6 weeks later is
indicated (1-way ANOVA with Tukey’s post-test; * P,0.05 ** and P,0.01).
doi:10.1371/journal.pone.0113951.s002 (TIF)
Figure S3. BCG vaccination-induced CD4+ and CD8+ T cells express cytolytic
potentials. Representative flow cytometry histograms demonstrate annexin-V
expression on the cell surface of WCL-pulsed target cells (i.e., CD32F4/80+
macrophages) from the (A) lung or (B) peritoneal lavage after co-culture with the
purified CD4+ (left) or CD8+ (right) T cells (at 1:20 ratio) from the pooled lungs
(upper panel) or spleens (lower panel) of BCG-vaccinated or age-matched naı̈ve
mice (n53/group). (*P,0.05, ** P,0.01, using 1-way ANOVA with Tukey’s
post-test compared to naı̈ve controls).
doi:10.1371/journal.pone.0113951.s003 (TIF)
Figure S4. CCR7 (TCM phenotype) expression by T cells following BCG
vaccination. The representative FACS plots demonstrate CCR-7 expression on the
unstimulated or WCL-stimulated CD4+ and CD8+ lung (A), spleen (B) and lymph
node T cells at week 12 (top) and week 52 (bottom) following i.n or s.c. BCG
vaccination of mice. Data are representative of pooled cells of four mice per time
point.
doi:10.1371/journal.pone.0113951.s004 (TIF)
Figure S5. Longitudinal changes in the CD8+ T-cell response of BCG vaccinated
and Mtb challenged mice. (A) The frequency of rESAT-6+rCFP-10-specific total
cytokine-positive (of IFN-c, IL-2 and TNF-a) CD8+ T cells from the lung (upper
panel) and spleen (lower panel) of BCG-vaccinated and naive mice 6 weeks after
challenge at five different time points using ICS. (*P,0.05 and **P,0.01
compared to the corresponding week 32 BCG-vaccinated mice by 1-way ANOVA
and Tukey’s post-test). At the 32-week time point the rESAT-6+rCFP-10-specific
response in the lung of naı̈ve mice is statistically higher compared to the
corresponding vaccinated groups (P,0.05). (B) The magnitude of WCL-specific
total cytokine-positive CD8+ T cells before and 6 weeks after Mtb challenge at
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seven different time points. The data are mean¡ s.e.m. responses of four mice
measured by ICS per time point per group.
doi:10.1371/journal.pone.0113951.s005 (TIF)
Text S1. Supplementary methods. Supplemental methods includes details of
tissue collection and immune cell isolation, ELISPOT and flow cytometry assay.
doi:10.1371/journal.pone.0113951.s006 (DOCX)
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